2017年美国心脏病学会/美国心脏协会(ACC/AHA)预防指南,检测,评价,和成人高血压的管理建议降低收缩压/舒张压(SBP/DBP)来定义高血压(即,通过将这些从≥140/90更改为≥130/80mmHg),包括关于抗高血压治疗的适应症和目标的新建议。这项研究报告了根据2017年ACC/AHA指南,根据美国成年人的种族,年龄调整后的高血压患病率和治疗状态的差异。对2011-16年度全国健康和营养检查调查数据进行了分析。主要结果是年龄调整后的患病率和年龄≥20岁成人高血压的治疗状况。在患病率估计之后,获得其他比例。分析包括16,103名成年人(平均年龄:47.6岁,51.8%妇女)。成人高血压患者的年龄调整比例(59.0%,95%置信区间[CI]:57.4%-60.6%),符合高血压治疗条件(49.3%,95%CI:47.7%-50.8%),和未达到的治疗目标(63.8%,95%CI:60.0%-67.5%)在接受治疗的人中,非西班牙裔黑人中最高。很大一部分墨西哥裔美国人(46.5%,95%CI:42.0%-51.0%)和其他种族/族裔的人(49.3%,95%CI:45.5%-53.0%)尽管有适应症,但未接受治疗。非西班牙裔黑人的2期高血压患病率最高。在所有种族中,患病率,治疗资格,未达到的治疗目标在老年人中更高,男性,糖尿病,体重较高,和更高的心血管疾病风险,而大多数年轻人,较低/正常体重,尽管有资格接受治疗,但非糖尿病患者仍未接受治疗.患病率,治疗资格,在非西班牙裔黑人中,未达到的目标明显较高。此外,尽管有适应症,但墨西哥裔美国人和“其他种族/种族”的人在治疗上存在差异。
The 2017 American College of Cardiology/American Heart Association (ACC/AHA)
Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults recommends reduced systolic/diastolic blood pressure (SBP/DBP) cutoffs to define hypertension (i.e., by changing these from ≥140/90 to ≥130/80 mmHg), including new recommendations about indications and goals of antihypertensive treatment. This study reported the differences in age-adjusted prevalence and treatment status of hypertension according to race among
US adults per the 2017 ACC/AHA
guideline. The National Health and Nutrition Examination Survey 2011-16 data was analyzed. The main outcomes were age-adjusted prevalence and treatment status of hypertension among adults aged ≥20 years. After prevalence estimation, other proportions were obtained. The analysis included 16,103 adults (mean age: 47.6 years, 51.8% women). The age-adjusted proportions of adults with hypertension (59.0%, 95% confidence interval [CI]: 57.4%-60.6%), treatment-eligible for hypertension (49.3%, 95% CI: 47.7%-50.8%), and unmet treatment goals (63.8%, 95% CI: 60.0%-67.5%) among the treated were highest among non-Hispanic blacks. A large proportion of Mexican-Americans (46.5%, 95% CI: 42.0%-51.0%) and people of other races/ethnicities (49.3%, 95% CI: 45.5%-53.0%) were not receiving treatment despite having indication. Non-Hispanic blacks also had the highest prevalence of stage 2 hypertension. Among all races, prevalence, treatment-eligibility, and unmet treatment goals were higher among people with older age, male gender, diabetes, higher body weight, and higher cardiovascular disease risk while the majority of younger, lower/normal body weight, or non-diabetic people were untreated despite being eligible for treatment. The prevalence, treatment-eligibility, and unmet goals were substantially higher among non-Hispanic blacks. Moreover, disparities exist in treatment where Mexican-Americans and people of \'other races/ethnicities\' were largely untreated despite having indication.